COLOVAC can help people with high genetic risk, such as FAP, precancerous polyps, or those who have been treated to remission after a colon cancer diagnosis. We anticipate a Phase I clinical trial for COLOVAC to begin within 3 years. Prevention is within reach.
#CancerVaccine
